Cargando…

Pantothenate Kinase 1 Inhibits the Progression of Hepatocellular Carcinoma by Negatively Regulating Wnt/β-catenin Signaling

Hyperactivation of Wnt/β-catenin signaling has been reported in hepatocellular carcinoma (HCC). However, the mechanisms underlying the hyperactivation of Wnt/β-catenin signaling are incompletely understood. In this study, Pantothenate kinase 1 (PANK1) is shown to be a negative regulator of Wnt/β-cat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zi, Yuyuan, Gao, Jie, Wang, Chenglv, Guan, Yidi, Li, Linzhao, Ren, Xinxin, Zhu, Lan, Mu, Yun, Chen, Shuang-hui, Zeng, Zimei, Cao, Zhen, Rong, Zhuoxian, Chen, Pan, Zhang, Xiuping, Chen, Tao, Xin, Haiguang, Li, Xuebing, Li, Zhi, Sun, Lunquan, Deng, Yuezhen, Li, Nan, Nie, Yingjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898371/
https://www.ncbi.nlm.nih.gov/pubmed/35280671
http://dx.doi.org/10.7150/ijbs.67842
Descripción
Sumario:Hyperactivation of Wnt/β-catenin signaling has been reported in hepatocellular carcinoma (HCC). However, the mechanisms underlying the hyperactivation of Wnt/β-catenin signaling are incompletely understood. In this study, Pantothenate kinase 1 (PANK1) is shown to be a negative regulator of Wnt/β-catenin signaling. Downregulation of PANK1 in HCC correlates with clinical features. Knockdown of PANK1 promotes the proliferation, growth and invasion of HCC cells, while overexpression of PANK1 inhibits the proliferation, growth, invasion and tumorigenicity of HCC cells. Mechanistically, PANK1 binds to CK1α, exerts protein kinase activity and cooperates with CK1α to phosphorylate N-terminal serine and threonine residues in β-catenin both in vitro and in vivo. Additionally, the expression levels of PANK1 and β-catenin can be used to predict the prognosis of HCC. Collectively, the results of this study highlight the crucial roles of PANK1 protein kinase activity in inhibiting Wnt/β-catenin signaling, suggesting that PANK1 is a potential therapeutic target for HCC.